Business news, market intelligence, and global industry analysis.
The Latest

Lupin subsidiary gets FDA approval for Fluocinolone Acetonide Oil

byPallavi Madhiraju
August 9, 2023
1 minute read
Total
0
Shares
0
0
0

Lupin Limited said that their wholly-owned US subsidiary, Novel Laboratories Inc., has secured approval from the US Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Fluocinolone Acetonide Oil, 0.01% (Body Oil). This product stands as the generic counterpart to DermaSmoothe/FS 0.01% (Body Oil) originally by Hill Dermaceuticals, Inc.

Commercial Impact and Production Details:

The market value of Fluocinolone Acetonide Oil, tracing back to its reference listed drug Derma-Smoothe/FS®, was approximated at annual sales of USD 10 million in the U.S. as per IQVIA MAT June 2023 figures. Reinforcing the announcement’s significance, Lupin divulged that the production of this approved product will be overseen at their dedicated Somerset facility in the US.

Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

See also  Can Avacta’s peptide drug conjugates rival ADCs? The next chapter in targeted cancer delivery
Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

JAVELIN Medley trial : First patient dosed with BAVENCIO, CMP-001 combo

Checkmate Pharmaceuticals announced the dosing of the first patient in a phase 1b/2 study of BAVENCIO (avelumab) in multi-drug combinations with its lead candidate CMP-001 in patients having squamous cell cancer of the head and neck (SCCHN), as part of the JAVELIN Medley trial. CMP‐001 is a C0pG‐A Toll‐like receptor 9 (TLR9) agonist that is […]

The post JAVELIN Medley trial : First patient dosed with BAVENCIO, CMP-001 combo appeared first on PharmaNewsDaily.com.

bypharmanewsdaily